Authors


Clara Bodelon, PhD, MS

Latest:

Consideration of Long-Term Physical Health Effects From Breast Cancer Therapies

“We see that those taking chemotherapy are going to be the ones that are going to require the most help,” Clara Bodelon, PhD, MS, said regarding breast cancer treatment.


Ankita Aggarwal, MD

Latest:

Erdheim-Chester Disease: A Case Report of BRAF V600E–Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review

Investigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.


Sigbjørn Berentsen, MD, PhD

Latest:

3 Things You Should Know About Hemolytic Anemias

Hemolytic anemias are a collection of rare but severe diseases including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.


Chasse Bailey-Dorton, MD, MSPH

Latest:

Integrative Oncology in Young Women With Breast Cancer

Yancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.


Armin Ghobadi, MD

Latest:

Armin Ghobadi, MD, on Recent Advancements in the Treatment of Patients with DLBCL

An expert in the treatment of diffuse large B-cell lymphoma explained some of the exciting advances in treatment and hypothesized what comes next after the 2020 ASH Annual Meeting & Exposition.


Rohit Gupta, MD

Latest:

Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head Mass

Rohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.


Susan Bal, MD

Latest:

BMS-986393 Appears Effective, Safe in Relapsed/Refractory Multiple Myeloma

GPRC5D may be a promising therapeutic pathway in the treatment of those with relapsed/refractory multiple myeloma, says Susan Bal, MD.


Leticia Nogueira, PhD, MPH

Latest:

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.


Joanna M. Rhodes, MD, MSCE

Latest:

Ensuring Safe Bispecific Antibody Use in Lymphoma at Community Practices

Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.


Hans Hammers, MD, PhD

Latest:

KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025

Experts discuss the KEYMAKER-U03 trial, highlighting lenvatinib plus belzutifan as a promising option in advanced renal cell carcinoma and new directions emerging from the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium.


Mary Katherine L. Anderson, MD

Latest:

Synovial Fluid in Checkpoint Inhibitor–Induced Inflammatory Arthritis

This case report and literature review emphasize that ICI-IA should not be ruled out based on the presence of synovial fluid with elevated WBC with a neutrophil predominance. Early steroid use should be considered.


Daniel M. Geynisman, MD

Latest:

Daniel M. Geynisman, MD, on Optimal Therapy Selection in RCC

At 2022 ASCO GU, Daniel M. Geynisman, MD, spoke with CancerNetwork® about his strategy for treating renal cell carcinoma across lines of therapy.


Raji Shameem, MD

Latest:

Debate: Optimal Initiation of ESAs, Luspatercept, and Imetelstat: Pretransfusion vs Posttransfusion

Panelists discuss the debate on optimal timing for initiating therapies in lower-risk myelodysplastic syndromes, balancing early intervention to improve quality of life and prevent complications against a conservative approach favoring treatment initiation upon transfusion dependency or symptom onset.


Satya Das, MD, MSCI

Latest:

Satya Das, MD, MSCI, on Research Presented at the 2021 ASCO Gastrointestinal Cancer Symposium

The expert in hematology/oncology discussed what research he is most looking forward to seeing the results of at the meeting.


Edward S. Kim, MD, MBA

Latest:

Future Therapies for ALK+ Metastatic NSCLC

Dr. Kim shares her insights on new investigational therapies for metastatic ALK+ NSCLC that she's particularly excited about.



Lorena Nascimento Manrique Molina, BS

Latest:

Psycho-Oncology and the Relevance of a Biopsychosocial Screening Program

Routine biopsychosocial screening of a patient with metastatic renal cell cancer at the Centro de Câncer de Brasília improved symptom management and shrunk costs for both the patient and her caregivers.


Michael J. Demeure, MD, MBA

Latest:

Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1

ABSTRACT Advances in immuno-oncology over the last several years have led to FDA approvals of novel agents. As our understanding of immune response and its checkpoints has evolved, further advances have been made in treatment for several cancer types. To predict a response to immunotherapy, the initial biomarkers used were expression of the PD-1 receptor and PD-L1, as assessed by immunohistochemistry. More recently, predictive biomarkers have included microsatellite instability, DNA mismatch repair, and tumor mutational burden. Although these markers may be clinically relevant in predicting an immunotherapy response, cancer immunotherapy fails some patients. Improved understanding of the human immune system is necessary, as is a careful evaluation of the methods used to predict and assess response to Immuno-oncology treatments. With the application of therapeutic immune-modulating agents, more comprehensive assays, and associated bioinformatics tools to accurately assess the tumor microenvironment, we may better predict responses to immuno-oncology agents and the ever-increasing complexity of their clinical use.





Dan Vogl, MD

Latest:

Treatment Response and Duration of Therapy in Transplant-Ineligible NDMM

Closing out their module on transplant-ineligible NDMM management, expert panelists consider best practices regarding duration of therapy and adjustments to drug regimens.


Andy Polhamus

Latest:

Triplet Induction Chemotherapy Improves FFS in Nasopharyngeal Carcinoma Vs Doublet Regimen

Patients with stage IVA to IVB nasopharyngeal carcinoma experienced an improvement in failure-free survival following treatment with paclitaxel, cisplatin, and capecitabine for 2 cycles vs 2 cycles of cisplatin and fluorouracil.




Yi-Bin Chen, MD

Latest:

Future Directions in Graft vs Host Disease Management

Closing out their panel on GVHD management, expert hematologist/oncologists share their hope for future evolution in the treatment landscape.


Shivananda S, BDS, MDS

Latest:

Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and Cancer

Human saliva may hold antioxidants that are able to monitor the oral cavity's oxidative processes and offer guidance for the development of new drugs.


Ken Shain, MD, PhD

Latest:

Future Perspectives: What’s Next in NDMM?

Panelists discuss how the treatment landscape for patients with transplant-ineligible/deferred newly diagnosed multiple myeloma (NDMM) is expected to evolve, with considerations for optimizing therapeutic approaches based on emerging data from novel drug combinations and treatment strategies.